Insider Trading Alert - SYK, DRE And PCG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, May 16, 2014, 187 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $632,004,766.20.

Highlighted Stocks Traded by Insiders:

Stryker Corporation (SYK) - FREE Research Report

Parfet William U, who is Director at Stryker Corporation, sold 2,062 shares at $80.10 on May 16, 2014. Following this transaction, the Director owned 272,119 shares meaning that the stake was reduced by 0.75% with the 2,062-share transaction.

The shares most recently traded at $80.17, up $0.07, or 0.09% since the insider transaction. Historical insider transactions for Stryker Corporation go as follows:

  • 4-Week # shares sold: 17,100
  • 12-Week # shares sold: 18,889
  • 24-Week # shares sold: 22,564

The average volume for Stryker Corporation has been 1.6 million shares per day over the past 30 days. Stryker Corporation has a market cap of $30.0 billion and is part of the health care sector and health services industry. Shares are up 6.6% year-to-date as of the close of trading on Friday.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The stock currently has a dividend yield of 1.54%. The company has a P/E ratio of 39.2. Currently, there are 13 analysts who rate Stryker Corporation a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYK - FREE

TheStreet Quant Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal